A disruption in iron-sulfur center biogenesis via inhibition of mitochondrial dithiol glutaredoxin 2 may contribute to mitochondrial and cellular iron dysregulation in mammalian glutathione-depleted dopaminergic cells: Implications for Parkinson's disease

Antioxidants and Redox Signaling

Volumn 11, Issue 9, 2009, Pages 2083-2094

  Lee, Donna W ^a   Kaur, Deepinder ^a   Chinta, Shankar J ^a   Rajagopalan, Subramanian ^a   Andersen, Julie K ^a  

^a BUCK INSTITUTE FOR RESEARCH ON AGING   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACONITATE HYDRATASE; FERRITIN; GLUTAREDOXIN; GLUTAREDOXIN 2; GLUTATHIONE; IRON; IRON REGULATORY PROTEIN 1; IRON SULFUR PROTEIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); SMALL INTERFERING RNA; TRANSFERRIN RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BIOGENESIS; CONTROLLED STUDY; EMBRYO; ENZYME ACTIVITY; MITOCHONDRION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN BINDING; RAT;

ANIMALS; BASE SEQUENCE; DOPAMINE; GENE KNOCKDOWN TECHNIQUES; GLUTAREDOXINS; GLUTATHIONE; IRON; IRON-SULFUR PROTEINS; MASS SPECTROMETRY; MITOCHONDRIA; PARKINSON DISEASE; RATS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING;

MAMMALIA;

EID: 68949203453     PISSN: 15230864     EISSN: None     Source Type: Journal    
DOI: 10.1089/ars.2009.2489     Document Type: Article

References (49)

1. Adams FS, La Rosa FG, Kumar S, Edwards-Prasad J, Kentroti S, Vernadakis A, Freed CR, and Prasad KN. Characterization and transplantation of two neuronal cell lines with dopaminergic properties. Neurochem Res 21: 619-627, 1996.
2. Auchere F, Santos R, Planamente S, Lesuisse E, and Camadro JM. Glutathione-dependent redox status of frataxin-deficient cells in a yeast model of Friedreich's ataxia. Hum Mol Genet 17: 2790-2802, 2008.
3. Balijepalli S, Tirumalai PS, Swamy K, Boyd V, Mieyal MR, Ravindranath JJ, and Rat V. Brain thioltransferase: regional distribution, immunological characterization, and localization by fluorescent in situ hybridization. J Neurochem 72: 1170-1178, 1999.
4. Bannon MJ, Goedert M, and Williams B. The possible relation of glutathione, melanin and 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) to Parkinson's disease. Biochem Pharmacol 33: 2697-2698, 1984.
5. Barker JE, Heales SJ, Cassidy A, Bolanos JP, Land J, Clark M, and Jones B. Depletion of brain glutathione results in a decrease of glutathione reductase activity; an enzyme susceptible to oxidative damage. Brain Res 716: 118-122, 1996.
6. Beal MF. Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses? Ann Neurol 31: 119-130, 1992.
7. Beer SM, Taylor ER, Brown SE, Dahm CC, Costa NJ, Runswick MJ, and Murphy MP. Glutaredoxin 2 catalyzes the reversible oxidation and glutathionylation of mitochondrial membrane thiol proteins: implications for mitochondrial redox regulation and antioxidant defense. J Biol Chem 279: 47939-47951, 2004.
8. Berndt C, Hudemann C, Hanschmann EM, Axelsson R, Holmgren A, and Lillig CH. How does iron-sulfur cluster coordination regulate the activity of human glutaredoxin 2? Antioxid Redox Signal 9: 151-157, 2007.
9. Biederbick A, Stehling O, Rosser R, Niggemeyer B, Nakai Y, Elsasser HP, and Lill R. Role of human mitochondrial Nfs1 in cytosolic iron-sulfur protein biogenesis and iron regulation. Mol Cell Biol 26: 5675-5687, 2006.
10. Burke RE. Programmed cell death and Parkinson's disease. Mov Disord 13(suppl 1): 17-23, 1998.
11. Chinta SJ and Andersen RK. Reversible inhibition of mitochondrial complex I activity following chronic dopaminergic glutathione depletion in vitro: implications for Parkinson's disease. Free Radic Biol Med 41: 1442-1448, 2006.
12. Chinta SJ, Kumar MJ, Hsu M, Rajagopalan S, Kaur D, Rane A, Nicholls DG, Choi J, and Andersen JK. Inducible alterations of glutathione levels in adult dopaminergic midbrain neurons result in nigrostriatal degeneration. J Neurosci 27: 13997-14006, 2007.
13. Cohen G and Kesler N. Monoamine oxidase and mitochondrial respiration. J Neurochem 73: 2310-2315, 1999.
14. Clarkson ED, Rosa FG, Edwards-Prasad J, Weiland DA, Witta SE, Freed CR, and Prasad KN. Improvement of neurological deficits in 6-hydroxydopamine- lesioned rats after transplantation with allogeneic simian virus 40 large tumor antigen gene-induced immortalized dopamine cells. Proc Natl Acad Sci U S A 95: 1265-1270, 1998.
15. Enoksson M, Fernandes AP, Prast S, Lillig CH, Holmgren A, and Orrenius S. Overexpression of glutaredoxin 2 attenuates apoptosis by preventing cytochrome c release. Biochem Biophys Res Commun 327: 774-779, 2005.
16. Epsztejn S, Kakhlon O, Glickstein H, Breuer W, and Cabantchik I. Fluorescence analysis of the labile iron pool of mammalian cells. Anal Biochem 248: 31-40, 1997.
17. Fernando MR, Lechner JM, Lofgren S, Gladyshev VN, and Lou MF. Mitochondrial thioltransferase (glutaredoxin 2) has GSH-dependent and thioredoxin reductase-dependent peroxidase activities in vitro and in lens epithelial cells. FASEB J 20: 2645-2647, 2006.
18. Forno LS. Neuropathology of Parkinson's disease. J Neuropathol Exp Neurol 55: 259-272, 1996.
19. Gladyshev VN, Liu A, Novoselov A, Krysan SV, Sun K, Kryukov QA, Kryukov VM, Lou GV, and M F. Identification and characterization of a new mammalian glutaredoxin (thioltransferase), Grx2. J Biol Chem 276: 30374-30380, 2001.
20. Hashemy SI, Johansson C, Berndt C, Lillig CH, and Holmgren A. Oxidation and s-nitrosylation of cysteines in human and mitochondrial glutaredoxins. J Biol Chem 282: 14428-14436, 2007.
21. Herrero E and de la Torre-Ruiz MA. Monothiol glutaredoxins: a common domain for multiple functions. Cell Mol Life Sci 64: 1518-1530, 2007.
22. Hsu M, Srinivas B, Kumar J, Subramanian R, and Andersen J. Glutathione depletion resulting in selective mitochondrial complex I inhibition in dopaminergic cells is via an NO-mediated pathway not involving peroxynitrite: implications for Parkinson's disease. J Neurochem 92: 1091-1103, 2005.
23. Jenner P. Altered mitochondrial function, iron metabolism and glutathione levels in Parkinson's disease. Acta Neurol Scand Suppl 146: 6-13, 1993.
24. Jha N, Jurma O, Lalli O, Liu G, Pettus Y, Greenamyre EH, Liu JT, Forman RM, Andersen HJ, and Andersen JK. Glutathione depletion in PC12 results in selective inhibition of mitochondrial complex I activity: implications for Parkinson's disease. J Biol Chem 275: 26096-26101, 2000.
25. Karunakaran S, Saeed U, Ramakrishnan S, Koumar RC, and Ravindranath V. Constitutive expression and functional characterization of mitochondrial glutaredoxin (Grx2) in mouse and human brain. Brain Res 1185: 817, 2007.
26. Kaur D, Lee DW, Rajagopalan S, and Andersen JK. Glutathione depletion in immortalized midbrain-derived dopaminergic neurons results in increases in the labile iron pool: implications for Parkinson's disease. Free Radic Biol Med 46: 593-598, 2009.
27. Li K, Besse EK, Ha D, Kovtunovych G, and Rouault TA. Iron-dependent regulation of frataxin expression: implications for treatment of Friedreich ataxia. Hum Mol Genet 17: 2265-2273, 2008.
28. Lillig CH, Berndt C, and Holmgren A. Glutaredoxin systems. Biochim Biophys Acta 1780: 1304-1317, 2008.
29. Lillig CH, Berndt C, Vergnolle O, Lonn ME, Hudemann C, Bill E, and Holmgren A. Characterization of human glutaredoxin 2 as iron-sulfur protein: a possible role as redox sensor. Proc Natl Acad Sci U S A 102: 8168-8173, 2005.
30. Lillig CH, Lonn ME, Enoksson M, Fernandes AP, and Holmgren A. Short interfering RNA-mediated silencing of glutaredoxin 2 increases the sensitivity of HeLa cells toward doxorubicin and phenylarsine oxide. Proc Natl Acad Sci U S A 101: 13227-13232, 2004.
31. Lundberg M, Fernandes AP, Kumar S, and Holmgren A. Cellular and plasma levels of human glutaredoxin 1 and 2 detected by sensitive ELISA systems. Biochem Biophys Res Commun 319: 801-809, 2004.
32. Lundberg M, Johansson C, Chandra C, Enoksson J, Jacobsson M, Ljung G, Johansson J, and Holmgren MA. Cloning and expression of a novel human glutaredoxin (Grx2) with mitochondrial and nuclear isoforms. J Biol Chem 276): 26269-26275, 2001.
33. Missirlis F, Holmberg S, Georgieva T, Dunkov BC, Rouault TA, and Law JH. Characterization of mitochondrial ferritin in Drosophila. Proc Natl Acad Sci U S A 103: 5893-5898, 2006.
34. Mieyal JJ, Gallogly MM, Qanungo S, Sabens EA, and Shelton MD. Molecular mechanisms and clinical implications of reversible protein S-glutathionylation. Antioxid Redox Signal 10: 1941-1988, 2008.
35. Pai HV, Starke DW, Lesnefsky EJ, Hoppel CL, and Mieyal JJ. What is the functional significance of the unique location of glutaredoxin 1 (GRx1) in the intermembrane space of mitochondria? Antioxid Redox Signal 9: 2027-2033, 2007.
36. Perry TL, Godin DV, Hansen S. Parkinson's disease: a disorder due to nigral glutathione deficiency? Neurosci Lett 33: 305-310, 1982.
37. Perry TL and Yong VW. Idiopathic Parkinson's disease, progressive supranuclear palsy and glutathione metabolism in the substantia nigra of patients. Neurosci Lett 67: 269-274, 1986.
38. Rodriguez-Manzaneque MT, Ros J, Cabiscol E, Sorribas A, and Herrero E. Grx5 glutaredoxin plays a central role in protection against protein oxidative damage in Saccharomyces cerevisiae. Mol Cell Biol 19: 8180-8190, 1999.
39. Rodriguez-Manzaneque MT, Tamarit J, Belli G, Ros J, and Herrero E. Grx5 is a mitochondrial glutaredoxin required for the activity of iron/sulfur enzymes. Mol Biol Cell 13: 1109-1121, 2002.
40. Rouault TA and Tong WH. Iron-sulfur cluster biogenesis and human disease. Trends Genet 24: 398-407, 2008.
41. Sagemark J, Elgan TH, Burglin TR, Johansson C, Holmgren A, and Berndt KD. Redox properties and evolution of human glutaredoxins. Proteins 68: 879-892, 2007.
42. Saeed U, Durgadoss L, Valli RK, Joshi DC, Joshi PG, and Ravindranath V. Knockdown of cytosolic glutaredoxin 1 leads to loss of mitochondrial membrane potential: implications in neurodegenerative diseases. PLoS ONE 3: e2459, 2008.
43. Schilling B, Bharath MM, Row RH, Murray J, Cusack MP, Capaldi RA, Freed CR, Prasad KN, Andersen JK, and Gibson BW. Rapid purification and mass spectrometric characterization of mitochondrial NADH dehydrogenase (Complex I) from rodent brain and a dopaminergic neuronal cell line. Mol Cell Proteomics 4: 84-96, 2005.
44. Schueck ND, Woontner M, and Koeller DM. The role of the mitochondrion in cellular iron homeostasis. Mitochondrion 1: 51-56, 2001.
45. Sipos K, Lange H, Fekete Z, Ullmann P, Lill R, and Kispal G. Maturation of cytosolic iron-sulfur proteins requires glutathione. J Biol Chem 277: 26944-26949, 2002.
46. Stehling O, Elsasser HP, Bruckel B, Muhlenhoff U, and Lill R. Iron-sulfur protein maturation in human cells: evidence for a function of frataxin. Hum Mol Genet 13: 3007-3015, 2004.
47. Trounce IA, Kim YL, Jun AS, and Wallace DC. Assessment of mitochondrial oxidative phosphorylation in patient muscle biopsies, lymphoblasts, and transmitochondrial cell lines. Methods Enzymol 264: 484-509, 1996.
48. Wang J, Boja ES, Tan W, Tekle E, Fales HM, English S, Mieyal JJ, and Chock P. B. Reversible glutathionylation regulates actin polymerization in A431 cells. J Biol Chem 276: 47763-47766, 2001.
49. Wingert RA, Galloway JL, Barut B, Foott H, Fraenkel P, Axe JL, Weber GJ, Dooley K, Davidson AJ, Schmid B, Paw BH, Shaw GC, Kingsley P, Palis J, Schubert H, Chen O, Kaplan J, and Zon LI. Deficiency of glutaredoxin 5 reveals Fe-S clusters are required for vertebrate haem synthesis. Nature 436: 1035-1039, 2005.